camrelizumab + capecitabine + eribulin + gemcitabine + vinorelbine

This is a combination regimen consisting of five distinct anticancer agents with different mechanisms of action. Camrelizumab is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor and acts as an immune checkpoint inhibitor to enhance antitumor immunity. Capecitabine is an oral prodrug that is metabolized to 5-fluorouracil (5-FU), inhibiting DNA synthesis in rapidly dividing cells. Eribulin is a synthetic analog of halichondrin B and functions as a microtubule dynamics inhibitor leading to mitotic arrest and apoptosis. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporation into DNA strands and inhibition of ribonucleotide reductase. Vinorelbine is a semi-synthetic vinca alkaloid that disrupts microtubule assembly during mitosis. This multi-agent regimen may be considered for heavily pretreated or advanced breast cancer patients—particularly triple-negative breast cancer (TNBC)—to maximize cytotoxicity through complementary mechanisms[1][2][3].

Other names

SHR-1210SHR1210SHR 1210AiRuiKacamrelizumab injectionXelodacapecitabine tabletsE7389E-7389E 7389Halaveneribulin mesylateGemzargemcitabine hydrochlorideNavelbine